TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Here's Why Abeona Therapeutics Popped Higher Today

The Motley Fool Logo The Motley Fool By Lee Samaha
Here's Why Abeona Therapeutics Popped Higher Today

Abeona Therapeutics saw a significant stock surge of over 25% after reporting strong Q3 earnings and positive updates on Zevaskyn, its gene therapy treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with major insurers now covering the treatment.

Insights
USARW   negative

Stock price dropped 13.42% due to perceived reduction in geopolitical tension around rare earth metals supply, which previously drove stock prices higher


ABEO   positive

Stock increased 25%, patient identification progressing, major insurers now covering treatment, expected revenue growth in 2026